Cristina Auger

List of Publications by Year
in descending order

61 papers	2,721 citations	257357 24 h-index	189801 50 g-index
63 all docs	63 docs citations	63 times ranked	3213 citing authors

#	ARTICLE	IF	CITATIONS
1	MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients. Nature Reviews Neurology, 2015, 11, 597-606.	4.9	422
2	Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain, 2015, 138, 1863-1874.	3.7	403
3	MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—clinical implementation in the diagnostic process. Nature Reviews Neurology, 2015, 11, 471-482.	4.9	354
4	Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. Lancet Neurology, The, 2020, 19, 234-246.	4.9	207
5	The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. Brain, 2018, 141, 1075-1084.	3.7	98
6	Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. Multiple Sclerosis Journal, 2013, 19, 1175-1181.	1.4	93
7	Neurofilament light chain level is a weak risk factor for the development of MS. Neurology, 2016, 87, 1076-1084.	1.5	85
8	Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor. Multiple Sclerosis Journal, 2018, 24, 301-312.	1.4	79
9	Value of 3T Susceptibility-Weighted Imaging in the Diagnosis of Multiple Sclerosis. American Journal of Neuroradiology, 2020, 41, 1001-1008.	1.2	68
10	Disability progression markers over 6–12 years in interferon-β-treated multiple sclerosis patients. Multiple Sclerosis Journal, 2018, 24, 322-330.	1.4	60
11	Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis. Neurology, 2019, 92, e1507-e1516.	1.5	49
12	Prognostic implications of epilepsy in glioblastomas. Clinical Neurology and Neurosurgery, 2015, 139, 166-171.	0.6	42
13	Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis. Neurology, 2016, 87, 1368-1374.	1.5	42
14	The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS. Multiple Sclerosis Journal, 2020, 26, 1658-1669.	1.4	41
15	Neurological damage after transcatheter aortic valve implantation compared with surgical aortic valve replacement in intermediate risk patients. Clinical Research in Cardiology, 2016, 105, 508-517.	1.5	40
16	Evaluating the response to glatiramer acetate in relapsing–remitting multiple sclerosis (RRMS) patients. Multiple Sclerosis Journal, 2014, 20, 1602-1608.	1.4	36
17	Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome. Neurology, 2021, 97, e1641-e1652.	1.5	35
18	Optic Nerve Topography in Multiple Sclerosis Diagnosis. Neurology, 2021, 96, e482-e490.	1.5	32

#	ARTICLE	IF	CITATIONS
19	Early predictors of multiple sclerosis after a typical clinically isolated syndrome. Multiple Sclerosis Journal, 2014, 20, 1721-1726.	1.4	31
20	MRI phenotypes with high neurodegeneration are associated with peripheral blood B-cell changes. Human Molecular Genetics, 2016, 25, 308-316.	1.4	31
21	Improved Automatic Detection of New T2 Lesions in Multiple Sclerosis Using Deformation Fields. American Journal of Neuroradiology, 2016, 37, 1816-1823.	1.2	30
22	Predictive value of early brain atrophy on response in patients treated with interferon β. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e132.	3.1	28
23	Lesion topographies in multiple sclerosis diagnosis. Neurology, 2017, 89, 2351-2356.	1.5	27
24	Ratio of T1-Weighted to T2-Weighted Signal Intensity as a Measure of Tissue Integrity: Comparison with Magnetization Transfer Ratio in Patients with Multiple Sclerosis. American Journal of Neuroradiology, 2020, 41, 461-463.	1.2	27
25	Diagnostic value of brain chronic black holes on T1-weighted MR images in clinically isolated syndromes. Multiple Sclerosis Journal, 2014, 20, 1471-1477.	1.4	25
26	Robust association between vascular habitats and patient prognosis in glioblastoma: An international multicenter study. Journal of Magnetic Resonance Imaging, 2020, 51, 1478-1486.	1.9	24
27	Brain Volume Loss During the First Year of Interferon€Beta Treatment in Multiple Sclerosis: Baseline Inflammation and Regional Brain Volume Dynamics. Journal of Neuroimaging, 2016, 26, 532-538.	1.0	21
28	Grey matter atrophy is associated with disability increase in natalizumab-treated patients. Multiple Sclerosis Journal, 2017, 23, 556-566.	1.4	21
29	MR Imaging in Monitoring and Predicting Treatment Response in Multiple Sclerosis. Neuroimaging Clinics of North America, 2017, 27, 277-287.	0.5	20
30	The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia. Multiple Sclerosis Journal, 2021, 27, 913-921.	1.4	20
31	Cervical Cord Atrophy and Long-Term Disease Progression in Patients with Primary-Progressive Multiple Sclerosis. American Journal of Neuroradiology, 2018, 39, 399-404.	1.2	17
32	Texture analysis in susceptibility-weighted imaging may be useful to differentiate acute from chronic multiple sclerosis lesions. European Radiology, 2020, 30, 6348-6356.	2.3	16
33	Menopause does not modify disability trajectories in a longitudinal cohort of women with clinically isolated syndrome and multiple sclerosis followed from disease onset. European Journal of Neurology, 2022, 29, 1075-1081.	1.7	16
34	Brain regional volume estimations with NeuroQuant and FIRST: a study in patients with a clinically isolated syndrome. Neuroradiology, 2019, 61, 667-674.	1.1	15
35	T1/T2-weighted ratio in multiple sclerosis: A longitudinal study with clinical associations. NeuroImage: Clinical, 2022, 34, 102967.	1.4	13
36	Cumulative Dose of Macrocyclic Gadolinium-Based Contrast Agent Improves Detection of Enhancing Lesions in Patients with Multiple Sclerosis. American Journal of Neuroradiology, 2017, 38, 1486-1493.	1.2	12

#	Article	IF	Citations
37	Should we systematically test patients with clinically isolated syndrome for auto-antibodies?. Multiple Sclerosis Journal, 2015, 21, 1802-1810.	1.4	10
38	Tumefactive inflammatory leukoencephalopathy in cocaine users: Report of three cases. Multiple Sclerosis and Related Disorders, 2020, 38, 101496.	0.9	10
39	A validation study of manual atrophy measures in patients with MultipleÂSclerosis. Neuroradiology, 2020, 62, 955-964.	1.1	10
40	CSF chitinase 3-like 1 is associated with iron rims in patients with a first demyelinating event. Multiple Sclerosis Journal, 2022, 28, 71-81.	1.4	10
41	Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsingâ€"remitting multiple sclerosis patients. Journal of Neurology, 2022, 269, 452-459.	1.8	10
42	Spinal Cord in Multiple Sclerosis: Magnetic Resonance Imaging Features and Differential Diagnosis. Seminars in Ultrasound, CT and MRI, 2016, 37, 396-410.	0.7	9
43	Measurement of Cortical Thickness and Volume of Subcortical Structures in Multiple Sclerosis: Agreement between 2D Spin-Echo and 3D MPRAGE T1-Weighted Images. American Journal of Neuroradiology, 2017, 38, 250-256.	1.2	9
44	Ammonium tetrathiomolybdate in the decoppering phase treatment of Wilson's disease with neurological symptoms: A case series. Brain and Behavior, 2020, 10, e01596.	1.0	9
45	Other noninfectious inflammatory disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 135, 425-446.	1.0	8
46	Beyond McDonald: updated perspectives on MRI diagnosis of multiple sclerosis. Expert Review of Neurotherapeutics, 2021, 21, 895-911.	1.4	7
47	Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 950-957.	1.4	7
48	Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations. Multiple Sclerosis Journal, 2018, 24, 721-727.	1.4	6
49	Differential effect of vascularity between longâ€•and shortâ€•term survivors with IDH1/2 wildâ€•type glioblastoma. NMR in Biomedicine, 2021, 34, e4462.	1.6	5
50	Magnetic resonance imaging findings in focalâ€•onset status epilepticus. European Journal of Neurology, 2022, 29, 3-11.	1.7	5
51	Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre. Journal of Neurology, 2022, 269, 1764-1772.	1.8	5
52	Assessment of automatic decision-support systems for detecting active T2 lesions in multiple sclerosis patients. Multiple Sclerosis Journal, 2022, 28, 1209-1218.	1.4	4
53	The role of pontine lesion location in differentiating multiple sclerosis from vascular risk factor-related small vessel disease. Multiple Sclerosis Journal, 2021, 27, 968-972.	1.4	3
54	Herpes simplex encephalitis in the context of immune checkpoint inhibitors: a complex interplay. Acta Neurologica Belgica, 2022, 122, 823-825.	0.5	3

#	Article	IF	Citations
55	Adding brain volume measures into response criteria in multiple sclerosis: the RÃo-4 score. Neuroradiology, 2021, 63, 1031-1041.	1.1	2
56	MR imaging findings in primary spinal cord glioblastoma. Radiology Case Reports, 2021, 16, 72-77.	0.2	2
57	SWI as an Alternative to Contrast-Enhanced Imaging to Detect Acute MS Lesions. American Journal of Neuroradiology, 2022, 43, 534-539.	1.2	2
58	Assessment of 2D conventional and synthetic MRI in multiple sclerosis. Neuroradiology, 2022, , .	1.1	2
59	Routine Gadolinium Use for MRI Follow-Up of Multiple Sclerosis: Counterpointâ€"Gadolinium Should Not Always Be Used to Assess Disease Activity. American Journal of Roentgenology, 2022, 219, 26-27.	1.0	1
60	Acquired hepatocerebral degeneration in a metastatic neuroendocrine tumor long-term survivor â€" an update on neuroendocrine neoplasmâ€™s treatment: A case report. World Journal of Hepatology, 2021, 13, 611-619.	0.8	0
61	Can Cognitive training Reignite Compensatory Mechanisms in Advanced Multiple Sclerosis Patients? An Explorative Morphological Network Approach. Neuroscience, 2022, , .	1.1	0